These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
8. The virologic, immunologic, and clinical effects of interleukin 2 with potent antiretroviral therapy in patients with moderately advanced human immunodeficiency virus infection: a randomized controlled clinical trial--AIDS Clinical Trials Group 328. Mitsuyasu R, Gelman R, Cherng DW, Landay A, Fahey J, Reichman R, Erice A, Bucy RP, Kilby JM, Lederman MM, Hamilton CD, Lertora J, White BL, Tebas P, Duliege AM, Pollard RB, AIDS Clinical Trials Group 328 Study Team. Arch Intern Med; 2007 Mar 26; 167(6):597-605. PubMed ID: 17389292 [Abstract] [Full Text] [Related]
9. Randomized, open-label study of the impact of two doses of subcutaneous recombinant interleukin-2 on viral burden in patients with HIV-1 infection and CD4+ cell counts of > or = 300/mm3: CPCRA 059. Abrams DI, Bebchuk JD, Denning ET, Davey RT, Fox L, Lane HC, Sampson J, Verheggen R, Zeh D, Markowitz NP, Terry Beirn Community Programs for Clinical Research on AIDS. J Acquir Immune Defic Syndr; 2002 Mar 01; 29(3):221-31. PubMed ID: 11873071 [Abstract] [Full Text] [Related]
10. Controlled trial of interleukin-2 infusions in patients infected with the human immunodeficiency virus. Kovacs JA, Vogel S, Albert JM, Falloon J, Davey RT, Walker RE, Polis MA, Spooner K, Metcalf JA, Baseler M, Fyfe G, Lane HC. N Engl J Med; 1996 Oct 31; 335(18):1350-6. PubMed ID: 8857018 [Abstract] [Full Text] [Related]
11. The HYDILE trial: efficacy and tolerance of a quadruple combination of reverse transcriptase inhibitors versus the same regimen plus hydroxyurea or hydroxyurea and interleukin-2 in HIV-infected patients failing protease inhibitor-based combinations. Lafeuillade A, Hittinger G, Chadapaud S, Maillefet S, Rieu A, Poggi C. HIV Clin Trials; 2002 Oct 31; 3(4):263-71. PubMed ID: 12187499 [Abstract] [Full Text] [Related]
12. Immunomodulators as adjunctive therapy for HIV-1 infection. Pett SL, Emery S. J Clin Virol; 2001 Oct 31; 22(3):289-95. PubMed ID: 11564594 [Abstract] [Full Text] [Related]
13. Predictors of virologic and clinical outcomes in HIV-1-infected patients receiving concurrent treatment with indinavir, zidovudine, and lamivudine. AIDS Clinical Trials Group Protocol 320. Demeter LM, Hughes MD, Coombs RW, Jackson JB, Grimes JM, Bosch RJ, Fiscus SA, Spector SA, Squires KE, Fischl MA, Hammer SM. Ann Intern Med; 2001 Dec 04; 135(11):954-64. PubMed ID: 11730396 [Abstract] [Full Text] [Related]
14. A randomized controlled trial evaluating the efficacy and safety of intermittent 3-, 4-, and 5-day cycles of intravenous recombinant human interleukin-2 combined with antiretroviral therapy (ART) versus ART alone in HIV-seropositive patients with 100-300 CD4+ T cells. de Boer AW, Markowitz N, Lane HC, Saravolatz LD, Koletar SL, Donabedian H, Yoshizawa C, Duliege AM, Fyfe G, Mitsuyasu RT. Clin Immunol; 2003 Mar 04; 106(3):188-96. PubMed ID: 12706405 [Abstract] [Full Text] [Related]
15. Interleukin-2 before antiretroviral therapy in patients with HIV infection: a randomized trial (ANRS 119). Molina JM, Levy Y, Fournier I, Hamonic S, Bentata M, Beck-Wirth G, Gougeon ML, Venet A, Madelaine I, Sereni D, Jeanblanc F, Boulet T, Simon F, Aboulker JP, Agence Nationale de Recherches sur le SIDA et les Hépatites Virales (ANRS) 119 Interstart Study Team. J Infect Dis; 2009 Jul 15; 200(2):206-15. PubMed ID: 19508157 [Abstract] [Full Text] [Related]
16. HIV viral load response to antiretroviral therapy according to the baseline CD4 cell count and viral load. Phillips AN, Staszewski S, Weber R, Kirk O, Francioli P, Miller V, Vernazza P, Lundgren JD, Ledergerber B, Swiss HIV Cohort Study, Frakfurt HIV Clinic Cohort, EuroSIDA Study Group. JAMA; 2001 Nov 28; 286(20):2560-7. PubMed ID: 11722270 [Abstract] [Full Text] [Related]
17. A randomized, partially blinded phase 2 trial of antiretroviral therapy, HIV-specific immunizations, and interleukin-2 cycles to promote efficient control of viral replication (ACTG A5024). Kilby JM, Bucy RP, Mildvan D, Fischl M, Santana-Bagur J, Lennox J, Pilcher C, Zolopa A, Lawrence J, Pollard RB, Habib RE, Sahner D, Fox L, Aga E, Bosch RJ, Mitsuyasu R, Adult AIDS Clinical Trials Group A5024 Protocol Team. J Infect Dis; 2006 Dec 15; 194(12):1672-6. PubMed ID: 17109338 [Abstract] [Full Text] [Related]
18. Randomized, controlled phase II trial of subcutaneous interleukin-2 in combination with highly active antiretroviral therapy (HAART) in HIV patients. Hengge UR, Goos M, Esser S, Exner V, Dötterer H, Wiehler H, Borchard C, Müller K, Beckmann A, Eppner MT, Berger A, Fiedler M. AIDS; 1998 Dec 03; 12(17):F225-34. PubMed ID: 9863864 [Abstract] [Full Text] [Related]
19. Treatment with highly active antiretroviral therapy in human immunodeficiency virus type 1-infected children is associated with a sustained effect on growth. Verweel G, van Rossum AM, Hartwig NG, Wolfs TF, Scherpbier HJ, de Groot R. Pediatrics; 2002 Feb 03; 109(2):E25. PubMed ID: 11826235 [Abstract] [Full Text] [Related]
20. Interleukin-2 accelerates CD4 cell reconstitution in HIV-infected patients with severe immunosuppression despite highly active antiretroviral therapy: the ILSTIM study--ANRS 082. Katlama C, Carcelain G, Duvivier C, Chouquet C, Tubiana R, De Sa M, Zagury L, Calvez V, Autran B, Costagliola D, ILSTIM. AIDS; 2002 Oct 18; 16(15):2027-34. PubMed ID: 12370501 [Abstract] [Full Text] [Related] Page: [Next] [New Search]